Book contents
- Rethinking Clinical Research
- Rethinking Clinical Research
- Copyright page
- Contents
- Acknowledgments
- Introduction
- Part I Fundamentals
- Part II Rethinking Research
- 4 Asking the Right Questions
- 5 Bias in Randomized Controlled Trials
- 6 Is Bigger Always Better?
- 7 Achieving Transparency
- 8 Understanding and Restraining Study Costs
- 9 Implementation
- 10 Health Outcomes
- 11 Confronting the Crises in Peer Review and Academic Publishing
- 12 Ontologies
- Part III Case Studies
- Index
- References
8 - Understanding and Restraining Study Costs
from Part II - Rethinking Research
Published online by Cambridge University Press: 13 March 2025
Book contents
- Rethinking Clinical Research
- Rethinking Clinical Research
- Copyright page
- Contents
- Acknowledgments
- Introduction
- Part I Fundamentals
- Part II Rethinking Research
- 4 Asking the Right Questions
- 5 Bias in Randomized Controlled Trials
- 6 Is Bigger Always Better?
- 7 Achieving Transparency
- 8 Understanding and Restraining Study Costs
- 9 Implementation
- 10 Health Outcomes
- 11 Confronting the Crises in Peer Review and Academic Publishing
- 12 Ontologies
- Part III Case Studies
- Index
- References
Summary
Clinical research is expensive: In 2024, the US National Institutes of Health will spend about $49 billion on research projects. Requesting sufficient resources to conduct a high-quality investigation must be balanced against a desire to use public funds prudently. Most studies are underbudgeted. In addition to funds for study personnel and the costs of evaluation and treatment, there may be costs associated with regulatory and scientific oversight, such as a research ethics committee, community advisory boards, information technology, study registration, and funds for study dissemination. Clinical research is a heterogeneous enterprise that usually requires personnel with a range of complementary expertise. This chapter offers guidance on constructing realistic budgets. In addition, we address the complicated issue of paying study participants, which raises important ethical issues. It is important to compensate participants for their time and discomfort. We review models on which to base participant compensation.
Information
- Type
- Chapter
- Information
- Rethinking Clinical ResearchMethodology and Ethics, pp. 160 - 176Publisher: Cambridge University PressPrint publication year: 2025
References
National Institutes of Health (NIH) Funding: FY1996-FY2024 (Congressional Research Service). (May 17, 2023).Google Scholar
Martin, L, Hutchens, M, Hawkins, C, Radnov, A. How much do clinical trials cost? Nat Rev Drug Discov. 2017; 16(6):381–382. doi:10.1038/nrd.2017.70.CrossRefGoogle ScholarPubMed
Donahue, PT, Grove, G, Stillman, C, et al. Estimating the financial costs associated with a phase III, multi-site exercise intervention trial: Investigating Gains in Neurocognition in an Intervention Trial of Exercise (IGNITE). Contemp Clin Trials. 2021; 105:106401. doi:10.1016/j.cct.2021.106401.CrossRefGoogle Scholar
Eisenstein, EL, Lemons, PW, Tardiff, BE, Schulman, KA, Jolly, MK, Califf, RM. Reducing the costs of phase III cardiovascular clinical trials. Am Heart J. 2005; 149(3):482–488. doi:10.1016/j.ahj.2004.04.049.CrossRefGoogle ScholarPubMed
Emanuel, EJ, Schnipper, LE, Kamin, DY, Levinson, J, Lichter, AS. The costs of conducting clinical research. J Clin Oncol. 2003; 21(22):4145–4150. doi:10.1200/JCO.2003.08.156.CrossRefGoogle ScholarPubMed
Johnston, SC, Rootenberg, JD, Katrak, S, Smith, WS, Elkins, JS. Effect of a US National Institutes of Health programme of clinical trials on public health and costs. Lancet. 2006; 367(9519):1319–1327. doi:10.1016/S0140-6736(06)68578-4.CrossRefGoogle Scholar
Larson, GS, Carey, C, Grarup, J, et al. Lessons learned: Infrastructure development and financial management for large, publicly funded, international trials. Clin Trials. 2016; 13(2):127–136. doi:10.1177/1740774515625974.CrossRefGoogle ScholarPubMed
McDonald, AM, Knight, RC, Campbell, MK, et al. What influences recruitment to randomised controlled trials? A review of trials funded by two UK funding agencies. Trials. 2006; 7:9. doi:10.1186/1745-6215-7-9.CrossRefGoogle ScholarPubMed
Moore, TJ, Zhang, H, Anderson, G, Alexander, GC. Estimated costs of pivotal trials for novel therapeutic agents approved by the US Food and Drug Administration, 2015–2016. JAMA Intern Med. 2018; 178(11):1451–1457. doi:10.1001/jamainternmed.2018.3931.CrossRefGoogle ScholarPubMed
Pascarella, G, Capasso, A, Nardone, A, et al. Costs of clinical trials with anticancer biological agents in an Oncologic Italian Cancer Center using the activity-based costing methodology. PLoS One. 2019; 14(1):e0210330. doi:10.1371/journal.pone.0210330.CrossRefGoogle Scholar
Raftery, J, Young, A, Stanton, L, et al. Clinical trial metadata: Defining and extracting metadata on the design, conduct, results and costs of 125 randomised clinical trials funded by the National Institute for Health Research Health Technology Assessment programme. Health Technol Assess. 2015; 19(11):1–138. doi:10.3310/hta19110.CrossRefGoogle ScholarPubMed
Sertkaya, A, Wong, HH, Jessup, A, Beleche, T. Key cost drivers of pharmaceutical clinical trials in the United States. Clin Trials. 2016; 13(2):117–126. doi:10.1177/1740774515625964.CrossRefGoogle ScholarPubMed
Stergiopoulos, S, Calvert, SB, Brown, CA, et al. Cost drivers of a hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia phase 3 clinical trial. Clin Infect Dis. 2018; 66(1):72–80. doi:10.1093/cid/cix726.CrossRefGoogle ScholarPubMed
Li, G, Sajobi, TT, Menon, BK, et al. Registry-based randomized controlled trials- what are the advantages, challenges, and areas for future research? J Clin Epidemiol. 2016; 80:16–24. doi:10.1016/j.jclinepi.2016.08.003.CrossRefGoogle ScholarPubMed
Rennane, S, Baker, L, Mulcahy, A. Estimating the cost of industry investment in drug research and development: A review of methods and results. Inquiry. 2021; 58:469580211059731. doi:10.1177/00469580211059731.CrossRefGoogle ScholarPubMed
Sertkaya, A, DeVries, R, Jessup, A, Beleche, T. Estimated cost of developing a therapeutic complex medical device in the US. JAMA Netw Open. 2022; 5(9):e2231609. doi:10.1001/jamanetworkopen.2022.31609.CrossRefGoogle ScholarPubMed
Wouters, OJ, McKee, M, Luyten, J. Estimated research and development investment needed to bring a new medicine to market, 2009–2018. JAMA. 2020; 323(9):844–853. doi:10.1001/jama.2020.1166.CrossRefGoogle Scholar
In brief: Uridine triacetate (Xuriden) for hereditary orotic aciduria. Med Lett Drugs Ther. 2016; 58(1491):e49.Google Scholar
McMurray, JJ, Packer, M, Desai, AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014; 371(11):993–1004. doi:10.1056/NEJMoa1409077.CrossRefGoogle ScholarPubMed
Kasenda, B, von Elm, E, You, J, et al. Prevalence, characteristics, and publication of discontinued randomized trials. JAMA. 2014; 311(10):1045–1051. doi:10.1001/jama.2014.1361.CrossRefGoogle ScholarPubMed
McLennan, S, Griessbach, A, Briel, M, Group MRTAM. Practices and attitudes of Swiss stakeholders regarding investigator-initiated clinical trial funding acquisition and cost management. JAMA Netw Open. 2021; 4(6):e2111847. doi:10.1001/jamanetworkopen.2021.11847.CrossRefGoogle ScholarPubMed
Nevens, H, Harrison, J, Vrijens, F, et al. Budgeting of non-commercial clinical trials: Development of a budget tool by a public funding agency. Trials. 2019; 20(1):714. doi:10.1186/s13063-019-3900-8.CrossRefGoogle ScholarPubMed
Belgium Health Care Knowledge Centre (KBHK). 2022 – KCE Trials 2022 Investigator-led call. Accessed July 27, 2023. https://kce.fgov.be/en/kce-trials/calls/2022-kce-trials-2022-investigator-led-call.Google Scholar
Sulmasy, LS, Bledsoe, TA, ACP Ethics PoaHRC. American college of physicians ethics manual: Seventh edition. Ann Intern Med. 2019; 170(2_Suppl):S1–S32. doi:10.7326/M18-2160.Google ScholarPubMed
Alturki, R, Schandelmaier, S, Olu, KK, et al. Premature trial discontinuation often not accurately reflected in registries: Comparison of registry records with publications. J Clin Epidemiol. 2017; 81:56–63. doi:10.1016/j.jclinepi.2016.08.011.CrossRefGoogle Scholar
Bennette, CS, Ramsey, SD, McDermott, CL, Carlson, JJ, Basu, A, Veenstra, DL. Predicting low accrual in the National Cancer Institute’s Cooperative Group Clinical Trials. J Natl Cancer Inst. 2016; 108(2). doi:10.1093/jnci/djv324.CrossRefGoogle ScholarPubMed
Briel, M, Olu, KK, von Elm, E, et al. A systematic review of discontinued trials suggested that most reasons for recruitment failure were preventable. J Clin Epidemiol. 2016; 80:8–15. doi:10.1016/j.jclinepi.2016.07.016.CrossRefGoogle ScholarPubMed
Carlisle, B, Kimmelman, J, Ramsay, T, MacKinnon, N. Unsuccessful trial accrual and human subjects protections: An empirical analysis of recently closed trials. Clin Trials. 2015; 12(1):77–83. doi:10.1177/1740774514558307.CrossRefGoogle ScholarPubMed
Bogin, V. Lasagna’s law: A dish best served early. Contemp Clin Trials Commun. 2022; 26:100900. doi:10.1016/j.conctc.2022.100900.CrossRefGoogle Scholar
Grady, C, Dickert, N, Jawetz, T, Gensler, G, Emanuel, E. An analysis of U.S. practices of paying research participants. Contemp Clin Trials. 2005; 26(3):365–375. doi:10.1016/j.cct.2005.02.003.CrossRefGoogle ScholarPubMed
United States. National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. The Belmont report: Ethical principles and guidelines for the protection of human subjects of research. DHEW Publication no (OS) 78-0012. The Commission; U.S. Govt. Print. Off.; 1978:p. 20.Google Scholar
Gelinas, L, Largent, EA, Cohen, IG, Kornetsky, S, Bierer, BE, Fernandez Lynch, H. A framework for ethical payment to research participants. N Engl J Med. 2018; 378(8):766–771. doi:10.1056/NEJMsb1710591.CrossRefGoogle ScholarPubMed
Largent, EA, Fernandez Lynch, H. Paying research participants: Regulatory uncertainty, conceptual confusion, and a path forward. Yale J Health Policy Law Ethics. 2017; 17(1):61–141.Google Scholar
Gelinas, L. On measuring attitudes about payment for research. J Med Ethics. 2020; 46(12):833–834. doi:10.1136/medethics-2020-106996.CrossRefGoogle ScholarPubMed
Gelinas, L, White, SA, Bierer, BE. Economic vulnerability and payment for research participation. Clin Trials. 2020; 17(3):264–272. doi:10.1177/1740774520905596.CrossRefGoogle ScholarPubMed
Halpern, SD, Karlawish, JH, Casarett, D, Berlin, JA, Asch, DA. Empirical assessment of whether moderate payments are undue or unjust inducements for participation in clinical trials. Arch Intern Med. 2004; 164(7):801–803. doi:10.1001/archinte.164.7.801.CrossRefGoogle ScholarPubMed
Lazovski, J, Losso, M, Krohmal, B, Emanuel, EJ, Grady, C, Wendler, D. Benefits and burdens of participation in a longitudinal clinical trial. J Empir Res Hum Res Ethics. 2009; 4(3):89–97. doi:10.1525/jer.2009.4.3.89.CrossRefGoogle Scholar
Dominguez, D, Jawara, M, Martino, N, Sinaii, N, Grady, C. Commonly performed procedures in clinical research: A benchmark for payment. Contemp Clin Trials. 2012; 33(5):860–868. doi:10.1016/j.cct.2012.05.001.CrossRefGoogle ScholarPubMed
Bureau of Labor Statistics. CPI Inflation calculator. Accessed July 27, 2023. https://data.bls.gov/cgi-bin/cpicalc.pl.Google Scholar
Ripley, E, Macrina, F, Markowitz, M, Gennings, C. Who’s doing the math? Are we really compensating research participants? J Empir Res Hum Res Ethics. 2010; 5(3):57–65. doi:10.1525/jer.2010.5.3.57.CrossRefGoogle ScholarPubMed
Klitzman, R, Albala, I, Siragusa, J, Nelson, KN, Appelbaum, PS. The reporting of monetary compensation in research articles. J Empir Res Hum Res Ethics. 2007; 2(4):61–67. doi:10.1525/jer.2007.2.4.61.CrossRefGoogle ScholarPubMed
Rosenberg, LE. Exceptional economic returns on investments in medical research. Med J Aust. 2002; 177(7):368–371. doi:10.5694/j.1326-5377.2002.tb04840.x.CrossRefGoogle ScholarPubMed
List, JA. The Voltage Effect: How to Make Good Ideas Great and Great Ideas Scale. Currency; 2022.Google Scholar
Blakemore, C, Davidson, J. Putting a value on medical research. Lancet. 2006; 367(9519):1293–1295. doi:10.1016/S0140-6736(06)68552-8.CrossRefGoogle ScholarPubMed
Gillum, LA, Gouveia, C, Dorsey, ER, et al. NIH disease funding levels and burden of disease. PLoS One. 2011; 6(2):e16837. doi:10.1371/journal.pone.0016837.CrossRefGoogle ScholarPubMed
Ballreich, JM, Gross, CP, Powe, NR, Anderson, GF. Allocation of National Institutes of Health Funding by disease category in 2008 and 2019. JAMA Netw Open. 2021; 4(1):e2034890. doi:10.1001/jamanetworkopen.2020.34890.CrossRefGoogle ScholarPubMed
Williams, RJ, Tse, T, DiPiazza, K, Zarin, DA. Terminated trials in the ClinicalTrials.gov results database: Evaluation of availability of primary outcome data and reasons for termination. PLoS One. 2015; 10(5):e0127242. doi:10.1371/journal.pone.0127242.Google ScholarPubMed
Lund, H, Robinson, KA, Gjerland, A, et al. Meta-research evaluating redundancy and use of systematic reviews when planning new studies in health research: A scoping review. Syst Rev. 2022; 11(1):241. doi:10.1186/s13643-022-02096-y.CrossRefGoogle ScholarPubMed
Glasziou, P, Djulbegovic, B, Burls, A. Are systematic reviews more cost-effective than randomised trials? Lancet. 2006; 367(9528):2057–2058. doi:10.1016/S0140-6736(06)68919-8.CrossRefGoogle ScholarPubMed
Anderson, BR, Gotlieb, EG, Hill, K, et al. Registry-based trials: A potential model for cost savings? Cardiol Young. 2020; 30(6):807–817. doi:10.1017/S1047951120001018.CrossRefGoogle ScholarPubMed
Accessibility standard: Unknown
Why this information is here
This section outlines the accessibility features of this content - including support for screen readers, full keyboard navigation and high-contrast display options. This may not be relevant for you.Accessibility Information
Accessibility compliance for the HTML of this chapter is currently unknown
and may be updated in the future.